Alkaline phosphatase (ALP) is a potential novel treatment target for CVD in CKD. Dr. Haarhaus discusses ALP-related mechanisms of increased CV risk and beneficial effects of the BET inhibitor apabetalone.
Epigenetic processes are involved in renal damage. Marta Ruiz-Ortega describes the role of vascular calcification and alkaline phosphatase (ALP) in CKD and effects of BET inhibition on vascular calcification.
Slides as educational service to PACE members and meeting participants
Slides as educational service to PACE members and meeting participants
Slides as educational service to PACE members and meeting participants
ERA-EDTA 2019 Epigenetics contribute to vascular calcification, which is a hallmark of CVD in CKD. Prof. Brandenburg explains how BET inhibition can interfere with factors and pathways associated with vascular calcification.